Skip to content

Cheng-Teng Ip

Center for Cognitive and Brain Sciences, University of Macau, Avenida da Universidade, Taipa, Macau SAR, China.

4 papers in the library · 6 citations · publishing 2025-2026

Papers

Subanesthetic ketamine alters EEG signal complexity: Implications for treatment stratification in depression.

Journal of affective disorders October 1, 2025 Weng-Lam Chan, Sebastian Olbrich, Xinwen Jiang et al. 3 citations

Ketamine, a drug that blocks NMDA receptors and is thought to boost neuroplasticity, increased whole-brain EEG signal complexity during infusion in patients with major depressive disorder (MDD), most of whom had treatment-resistant depression. Higher complexity at the end of infusion predicted less symptom improvement the next day, while lower occipital complexity before treatment predicted a favorable response. A logistic model using occipital complexity had moderate predictive accuracy. No changes were seen in a different complexity measure, suggesting it is not useful as a biomarker. Occipital EEG complexity may help predict which patients will benefit from ketamine therapy.

DOI: 10.1016/j.jad.2025.119477 Full text Mdd Lempel-ziv complexity Treatment response Depression treatment +4

EEG vigilance and response to oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized validation study.

Psychiatry research. Neuroimaging July 1, 2025 Anna Monn, Corinne Eicher, Annia Rüesch et al. 2 citations

A higher percentage of EEG vigilance stage A1, a measure of brain activity, is associated with response to intravenous ketamine in major depression. In a phase-2 randomized controlled trial of oral prolonged-release ketamine for treatment-resistant depression, no significant interaction between response and treatment was found for this EEG marker. However, a small-scale meta-analysis showed a significant pooled mean difference between ketamine responders and non-responders. Applying a previously proposed A1 cutoff of 43% yielded chance-level prediction accuracy in the combined ketamine group but 75% accuracy in the 240 mg subgroup. Responders to 240 mg ketamine also showed more stable vigilance over time. These findings support EEG vigilance as a predictive biomarker for treatment outcomes in depression, though further validation is needed.

DOI: 10.1016/j.pscychresns.2025.112001 Full text Treatment-resistant depression Biomarkers biomarker Biological marker Molecular marker +5

Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 1, 2026 Cheng-Teng Ip, Sebastian Olbrich, Mateo de Bardeci et al. 1 citation

In a double-blind, randomized, crossover, placebo-controlled trial with 25 healthy adults, psilocybin (10–20 mg oral) decreased EEG power in slow frequency bands (theta and alpha) and increased power in fast frequency bands (beta, gamma1, gamma2) compared to placebo. Connectivity within the default-mode network and localized parietal network increased under psilocybin. Changes in EEG power and connectivity correlated positively with subjective experiences measured by the Altered States of Consciousness Questionnaire. Baseline EEG features predicted subjective alterations, suggesting that specific brain activity patterns could serve as biomarkers for tailoring psilocybin therapy.

DOI: 10.1016/j.pnpbp.2026.111626 Electroencephalography Dynamics music Neurophysiology Artificial neural network +4

Ketamine alters the aperiodic EEG exponent in major depression: implications for cortical E/I balance and treatment prediction.

Therapeutic advances in psychopharmacology January 1, 2026 Yujuan Liu, Xiaorong Liu, Sebastian Olbrich et al.

Ketamine, a rapid-acting antidepressant for treatment-resistant depression, may work by altering the brain's excitation-inhibition balance, measurable via the aperiodic exponent of EEG power spectra. In a placebo-controlled trial of 24 patients with major depressive disorder, ketamine infusion significantly reduced the aperiodic exponent across the scalp. Patients who responded to treatment had steeper pretreatment occipital aperiodic exponents, which predicted better outcomes. A meta-analysis within the study revealed substantial variability in ketamine's effect on this measure. The occipital aperiodic exponent may serve as a biomarker for predicting antidepressant response, but further large-scale studies are needed.

DOI: 10.1177/20451253261462240 Full text Ketamine E/i balance EEG Aperiodic exponent +1